Cytek Biosciences, Inc.

CTKB Healthcare Medical Devices

Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024. In the quarter to June 2026, revenue grew 5.57%, EPS fell 125.0%, free cash flow grew 42.5% and total debt fell 68.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

5.24 0.17 −3.14%
Market cap
$703.2M
P/E
0.0×
Fwd P/E
−11.7×
Dividend yield
—
F-score
4/9
Altman Z
3.89
Beneish M
−3.30
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 4 4 4
ROE
(3.36%) (18.05%) (20.93%) (23.04%)
ROA
(2.60%) (13.85%) (15.89%) (17.14%)
ROIC
(16.92%) (31.26%) (41.67%) (46.36%)
Return on Tangible Assets
(3.87%) (20.03%) (23.21%) (25.63%)
Average Days of Receivables
105.02 113.23 92.79 87.76
Free Cash Flow per Share
(0.04) (0.07) (0.10) (0.09)
Free Cash Flow
(5.73) (8.62) (12.61) (11.97)
Other line items

Show all line items

Columns are period end dates